Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Multi-Center, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Plasma Exposure of TD-1473 in Subjects With Moderately-to-Severely Active Ulcerative Colitis

NCT02818686 is registered in ClinicalTrials.gov with Theravance Biopharma as lead sponsor.

NCT NCT02818686
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02818686 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Multi-Center, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Plasma Exposure of TD-1473 in Subjects With Moderately-to-Severely Active Ulcerative Colitis
Lead sponsor
Theravance Biopharma
Phase
Phase 1
Overall status
Completed
Start date
October 3, 2016
Completion date
March 29, 2018
Enrollment
40 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis, active moderate, ulcerative colitis, active severe